Meeting
2023 ASCO Annual Meeting
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
Authors
Timothy J. Panella
University of Tennessee Medical Center at Knoxville, Knoxville, TN
Timothy J. Panella , Sajeve Samuel Thomas , Meredith McKean , Kim Allyson Margolin , Ryan Michael Weight , Jayakumar Mani , Shraddha Patel , Priya Desai , Mark Salvati , Israel Lowy , Matthew G. Fury , Giuseppe Gullo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05608291
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9598)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9598
Abstract #
TPS9598
Poster Bd #
358a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
First Author: Nikhil I. Khushalani
Poster
2023 ASCO Annual Meeting
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
First Author: Ana Baramidze
Poster
2019 ASCO Annual Meeting
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.
First Author: Matteo S. Carlino
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
First Author: Jason J. Luke